Clinical Data Maze tumbles despite positive data for kidney disease drug BioPharma DiveInvestors had reservations about data for a drug that could compete with a candidate from Vertex in APOL1-mediated kidney disease.Clinical DataRare DiseaseRead full story pharminent March 25, 2026 (Last updated: March 26, 2026) BioPharma Dive Investors had reservations about data for a drug that could compete with a candidate from Vertex in APOL1-mediated kidney disease. Clinical DataRare DiseaseRead full story Post navigation Previous: Beam posts positive data on base editing treatment for AATDNext: Wave crashes on obesity drug update; Kodiak’s reboot pays dividends Related Stories Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026 Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026
